A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants

Overseen By There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Eli Lilly and Company

Disqualifiers: Cancer, Malignant disease, others

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

33 Participants Needed

Trial Summary

Do I need to stop my current medications to join the trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, since the study is for healthy participants, it's possible that taking medications could affect eligibility.

What is the purpose of this trial?

This trial tests a new drug, LY3462817, to see if it is safe and how the body handles it. Healthy Japanese and non-Japanese people will participate. Researchers will measure how fast the drug gets into the blood and how long it takes to leave.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

Inclusion Criteria

You are a non-Japanese participant.

You are of childbearing potential.

You have the necessary medical and psychological conditions for the study.

Exclusion Criteria

Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study

Have previously participated or withdrawn from this study

Have cancer or a malignant disease in the past 5 years

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive LY3462817 or placebo, administered subcutaneously or intravenously

12 weeks

Multiple visits for drug administration and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• LY3462817

Participant Groups

Group I: LY3462817 - SC Experimental Treatment 1 Intervention

LY3462817 administered subcutaneously (SC)

Group II: LY3462817 - IV Experimental Treatment 1 Intervention

LY3462817 administered intravenously (IV)

Group III: Placebo - IV Placebo Group 1 Intervention

Placebo administered IV

Group IV: Placebo - SC Placebo Group 1 Intervention

Placebo administered SC

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials

2,708

Recruited

3,720,000+

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University